FDA Drug Recalls

Recalls / Class II

Class IID-0163-2025

Product

DULoxetine DR USP, 30 mg, 90-count bottle, Rx Only, Packaged by: PD Rx Pharmaceuticals Inc, Oklahoma City, OK 73127, NDC: 43063-877-90

Brand name
Duloxetine
Generic name
Duloxetine Hydrochloride
Active ingredient
Duloxetine Hydrochloride
Route
Oral
NDC
43063-877
FDA application
ANDA090778
Affected lot / code info
Lot # I24E77, A24E49, Exp Date: 04/30/25; J23C50, J23C97, L23B39, L23E98, Exp Date: 01/31/2025

Why it was recalled

CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

Recalling firm

Firm
PD-Rx Pharmaceuticals, Inc.
Notification channel
E-Mail
Type
Voluntary: Firm initiated
Address
727 N Ann Arbor Ave, Oklahoma City, Oklahoma 73127-5822

Distribution

Quantity
70, 90-count bottles
Distribution pattern
Distributed within US: FL, MS, WI

Timeline

Recall initiated
2024-12-04
FDA classified
2024-12-23
Posted by FDA
2025-01-01
Terminated
2025-03-21
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0163-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.